Vijayakumar S, Quadri S F, Dong L, Ignacio L, Kathuria I N, Sutton H, Halpern H
Department of Radiation Oncology, Michael Reese Hospital, Center for Radiation Therapy, University of Chicago, Illinois, USA.
J Natl Med Assoc. 1995 Nov;87(11):813-9.
This cross-sectional study was undertaken to determine whether serum hormones (free testosterone, androstenedione, luteinizing hormone, or prolactin) have any influence on serum prostate specific antigen (PSA) levels in patients with stage A-C prostate cancer. Blood samples were collected prior to any treatment in 36 patients; in 19 (group 1), three blood samples were collected 10 minutes apart between 9:00 AM and 9:30 AM for each patient and pooled together to avoid diurnal and episodic variation in serum testosterone values. In the remaining patients, only one sample could be collected (group 2). Free testosterone, androstenedione, luteinizing hormone, prolactin, and PSA levels were determined with appropriate radioimmunoassay techniques. Statistical analyses were performed separately for groups 1 and 2, and then with pooled data. None of the hormones in any of the analyses showed any association to serum PSA values except for prolactin for the pooled data and for group 2. This statistical significance for prolactin disappeared on multivariate analysis. There were 21 African-American men and 15 whites in the study; no racial differences in hormonal levels were found except for lower luteinizing hormone levels in African Americans in group 2 and pooled data. No differences were found between group 1 and group 2 in the mean serum prolactin and luteinizing hormone values. Serum free testosterone, androstenedione, and luteinizing hormone appeared to have no influence on serum PSA values in nonmetastatic cancer patients. Serum prolactin values were inversely associated with PSA values in univariate analysis for the pooled data; this disappeared in multivariate analysis. Unlike other studies that found higher serum testosterone levels in African-American college students than whites, no such differences were seen in this age group. Luteinizing hormone was lower in African-American men than in whites in the pooled study population. Further studies are needed to clarify our findings.
本横断面研究旨在确定血清激素(游离睾酮、雄烯二酮、促黄体生成素或催乳素)是否对A - C期前列腺癌患者的血清前列腺特异性抗原(PSA)水平有任何影响。在36例患者接受任何治疗之前采集血样;其中19例(第1组),为每位患者在上午9:00至9:30之间每隔10分钟采集三份血样并合并在一起,以避免血清睾酮值出现昼夜和间歇性变化。其余患者仅采集一份样本(第2组)。采用适当的放射免疫测定技术测定游离睾酮、雄烯二酮、促黄体生成素、催乳素和PSA水平。对第1组和第2组分别进行统计分析,然后对汇总数据进行分析。除汇总数据和第2组中的催乳素外,任何分析中的激素均未显示与血清PSA值有任何关联。催乳素的这种统计学显著性在多变量分析中消失。研究中有21名非裔美国男性和15名白人;除第2组和汇总数据中非洲裔美国人的促黄体生成素水平较低外,未发现激素水平存在种族差异。第1组和第2组的平均血清催乳素和促黄体生成素值无差异。血清游离睾酮、雄烯二酮和促黄体生成素似乎对非转移性癌症患者的血清PSA值没有影响。在汇总数据的单变量分析中,血清催乳素值与PSA值呈负相关;在多变量分析中这种相关性消失。与其他发现非裔美国大学生血清睾酮水平高于白人的研究不同,在这个年龄组中未观察到此类差异。在汇总研究人群中,非洲裔美国男性的促黄体生成素低于白人。需要进一步研究以阐明我们的发现。